aminopeptidas
n
recent
identifi
molecular
target
cholesterol
absorpt
inhibitor
ezetimib
regard
express
lipid
raft
monocyt
cell
investig
whether
ezetimib
influenc
raft
function
cell
express
raftassoci
antigen
follow
flow
cytometri
andor
immunoblot
human
monocytederiv
macrophag
respons
vitro
administr
ezetimib
cellular
redistribut
assess
confoc
imag
ezetimib
significantli
decreas
surfac
express
furthermor
induc
shift
plasma
membran
intracellular
vesicl
thu
quit
like
modul
monocyt
raftassembl
q
aminopeptidas
n
transmembran
ectoenzym
zinc
metalloproteas
broad
express
cellstissu
includ
myeloid
cell
hepatocyt
variou
epitheli
cell
nervou
system
placenta
involv
certain
biolog
process
growth
invas
tumor
cellular
motil
regul
angiogenesi
cellular
intern
human
coronaviru
modul
effect
neuropeptid
chemotact
peptid
refer
therein
recent
implic
molecular
target
ezetimib
azetidinonetyp
cholesterol
absorpt
inhibitor
plasma
cholesterol
lower
drug
enterocyt
brush
border
membran
raft
microdomainresid
type
ii
membran
protein
homodimer
polypeptid
short
cytoplasm
domain
eight
amino
acid
residu
describ
signal
motif
thu
tempt
specul
signal
transduct
requir
addit
membran
protein
quit
like
local
raft
recent
studi
minaosorio
ortega
provid
evid
function
interact
fcg
receptor
monocyt
cell
character
fluoresc
reson
energi
transfer
fret
human
monocyt
contain
raftassoci
constitut
receptor
cluster
activ
monocyt
lipopolysaccharid
lp
lipoteicho
acid
lead
coassembl
tolllik
raft
sinc
ezetimib
bind
quit
like
interact
receptor
raft
microdomain
investig
whether
ezetimib
influenc
assembl
monocyt
raft
express
raftassoci
antigen
monocyt
healthi
volunt
isol
leukapheresi
follow
counterflow
elutri
inform
consent
cell
cultur
serumfre
macrophag
medium
sfm
gibcoinvitrogen
karlsruh
germani
contain
ngml
recombin
human
macrophagecoloni
stimul
factor
mcsf
r
system
wiesbaden
germani
without
supplement
lm
ezetimib
aventi
pharma
frankfurt
main
germani
day
percentag
damag
ie
apoptot
necrot
cell
determin
propidium
iodid
exclus
irrespect
treatment
deterg
lysi
lubrol
wx
serva
heidelberg
germani
sucros
gradient
flotat
carri
describ
previous
immunoblot
cellular
fraction
whole
cell
lysat
perform
describ
earlier
use
mab
santa
cruz
biotechnolog
heidelberg
germani
cell
cultur
sodium
borosil
coverglass
nunc
wiesbaden
germani
fix
paraformaldehyd
polysci
eppelheim
germani
permeabil
triton
sigmaaldrich
label
accord
standard
procedur
addit
stain
plasma
membran
also
visual
mous
antihuman
annexin
ii
clone
bd
bioscienc
texa
redconjug
hors
antimous
igg
vector
laboratoriesalexi
gruenberg
germani
confoc
imag
taken
tc
invert
confoc
laser
scan
microscop
leica
lasertechnik
bensheim
germani
analyz
metamorph
softwar
packag
univers
imag
glendal
wi
ezetimib
significantli
decreas
surfac
express
monocytederiv
macrophag
mark
effect
surfac
express
fig
explor
whether
decreas
surfac
express
relat
cellular
intern
cellular
distribut
ezetimibtr
cell
investig
confoc
imag
control
cell
substanti
part
detect
cell
surfac
show
extens
coloc
plasma
membran
marker
annexin
ii
contrast
ezetimibtr
cell
major
coloc
annexin
ii
occur
cytoplasm
vesicl
thu
ezetimib
quit
like
induc
redistribut
annexin
ii
plasma
membran
intracellular
vesicl
fig
lysi
cell
lubrol
wx
follow
sucros
flotat
gradientsepar
confirm
presenc
deterg
resist
membran
drm
ie
raft
control
cell
wherea
elicit
deterg
solubl
ie
nonraft
fraction
respons
ezetimib
fig
parallel
mark
chang
cellular
redistribut
ezetimib
also
decreas
total
cellular
content
fig
ezetimib
lipidlow
drug
inhibit
intestin
cholesterol
absorpt
unknown
cellular
mechan
requir
bind
ezetimib
enterocyt
brush
border
bind
site
ezetimib
differ
aminopeptidas
activ
antigen
sinc
constitut
express
lipid
raft
monocytesmacrophag
tempt
specul
ezetimib
influenc
structur
andor
function
raft
cell
inde
present
studi
provid
evid
ezetimib
modul
cellular
redistribut
express
monocytederiv
macrophag
moreov
express
raftassoci
antigen
fcg
receptor
scaveng
receptor
extens
implic
cellular
uptak
modifi
lipoprotein
phagocytosi
also
downregul
respons
ezetimib
decreas
express
receptor
upon
ezetimib
administr
may
lead
impair
macrophagedifferenti
lipiduptak
thu
ezetimib
quit
like
exert
vitro
antiatherogen
effect
monocytederiv
macrophag
involv
raft
requir
coreceptor
subsequ
signal
demonstr
put
antigen
ezetimib
may
exert
cellular
effect
disrupt
coassembl
scenario
miss
coassoci
receptor
may
lead
disappear
raft
find
disappear
drmsraft
respons
ezetimib
fig
may
support
hypothesi
bind
ezetimib
quit
like
induc
conform
chang
extracellular
domain
mask
specif
sequenc
requir
coassoci
receptor
mechan
recent
propos
ezetimib
enterocyt
altern
shed
respons
ezetimib
may
also
explain
loss
express
summari
ezetimib
like
modifi
raft
assembl
monocytederiv
macrophag
dissoci
preclust
receptor
complex
